Tuberculosis-Related Uveitis in Patients under Anti-TNF-alpha Therapy: A Case Series

被引：4

作者：

Hernanz, I ^{[1
]}

Miguel Escuder, L. ^{[1
]}

Chamorro, L. ^{[1
]}

Moll-Udina, A. ^{[1
,2
]}

Espinosa, G. ^{[1
,2
]}

Sainz de la Maza, M. ^{[1
,2
]}

Llorenc, V ^{[1
,2
]}

Adan, A. ^{[1
,2
]}

机构：

[1] Univ Barcelona, Hosp Clin Barcelona, Clin Inst Ophthalmol, Barcelona, Spain

[2] Biomed Res Inst August Pi I Sunyer IDIBAPS, Barcelona, Spain

来源：

OCULAR IMMUNOLOGY AND INFLAMMATION | 2022年 / 30卷 / 04期

关键词：

Tuberculosis; uveitis; anti-TNF therapy; latent tuberculosis infection; adalimumab; infliximab; Behç et disease; spondyloarthropaties; ankylosing spondylitis; Crohn’ s disease; NONINFECTIOUS UVEITIS; ADALIMUMAB; PREVENTION; EFFICACY; SAFETY; RISK;

D O I：

10.1080/09273948.2020.1834588

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Tumor necrosis factor inhibitors (anti-TNF) have emerged as an effective treatment in noninfectious uveitis (NIU). Anti-TNF may increase the predisposition to infectious disease as tuberculosis (TB). TB-related uveitis in the context of an uveitogenic concurrent systemic immune-mediated disease under anti-TNF treatment remain a diagnostic challenge, deserving special focus on this rare context. Retrospective chart review of patients on anti-TNF drugs for systemic immune-mediated diseases that developed a multicentric microbiologically confirmed active TB with concurrent intraocular involvement. Three patients were recorded. Screening for TB before starting anti-TNF resulted negative in two patients. The other patient had received anti-tuberculous treatment in the past. All showed a microbiologically confirmed extraocular TB after unexpected atypical reactivation of the uveitis shifting to chronic granulomatous pattern. Specialists should be aware of TB reactivation, even with previous negative screening, when ocular uveitis signs and activity do not match with the expected pattern in a patient on anti-TNF drugs.

引用

页码：839 / 844

页数：6

共 30 条

[1] The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings [J].

Agrawal, Rupesh ;

Testi, Ilaria ;

Mahajan, Sarakshi ;

Yuen, Yew Sen ;

Agarwal, Aniruddha ;

Rousselot, Andres ;

Raje, Dhananjay ;

Gunasekeran, Dinesh Visva ;

Kon, Onn Min ;

Barisani-Asenbauer, Talin ;

Kempen, John H. ;

Gupta, Amod ;

Jabs, Douglas A. ;

Smith, Justine R. ;

Bodaghi, Bahram ;

Zierhut, Manfred ;

DeSmet, Marc ;

Mc Cluskey, Peter ;

Agarwal, Mamta ;

Agarwal, Manisha ;

Aggarwal, Kanika ;

Agrawal, Mukesh ;

Al-Dhibi, Hassan ;

Androudi, Sofia ;

Asyari, Fatma ;

Balasundaram, Manohar Babu ;

Murthy, Kalpana Babu ;

Baglivo, Edoardo ;

Banker, Alay ;

Bansal, Reema ;

Basu, Soumyava ;

Behera, Digamber ;

Biswas, Jyotirmay ;

Carreno, Ester ;

Caspers, Laure ;

Chee, Soon Phaik ;

Chhabra, Romi ;

Cimino, Luca ;

del Rio, Luz Elena Concha ;

Cunningham, Emmett T. ;

Curi, Andre Luiz Land ;

Das, Dipankar ;

Denisova, Ekaterina ;

Denniston, Alastair K. ;

Errera, Marie-Helene ;

Fonollosa, Alejandro ;

George, Amala ;

Goldstein, Debra A. ;

Crosier, Yan Guex ;

Gurbaxani, Avinash .

OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 :85-95

[2] Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1 [J].

Agrawal, Rupesh ;

Gunasekeran, Dinesh Visva ;

Grant, Robert ;

Agarwal, Aniruddha ;

Kon, Onn Min ;

Quan Dong Nguyen ;

Pavesio, Carlos ;

Gupta, Vishali .

JAMA OPHTHALMOLOGY, 2017, 135 (12) :1318-1327

[3] Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: a case-control study [J].

Ang, Marcus ;

Hedayatfar, Alireza ;

Wong, Wanling ;

Chee, Soon-Phaik .

BRITISH JOURNAL OF OPHTHALMOLOGY, 2012, 96 (03) :332-336

[4]

Atlanta GUSD of Health and Human Services C. CDC, 2002, REP TUB US

[5] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents) [J].

Baddley, J. W. ;

Cantini, F. ;

Goletti, D. ;

Gomez-Reino, J. J. ;

Mylonakis, E. ;

San-Juan, R. ;

Fernandez-Ruiz, M. ;

Torre-Cisneros, J. .

CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 :S10-S20

[6] Factors Affecting the Tuberculosis Risk in Patients Receiving Anti-Tumor Necrosis Factor-α Treatment [J].

Borekci, Sermin ;

Atahan, Ersan ;

Yilmaz, Deniz Demir ;

Mazican, Nejdiye ;

Duman, Berna ;

Ozguler, Yesim ;

Musellim, Benan ;

Hamuryudan, Vedat ;

Ongen, Gul .

RESPIRATION, 2015, 90 (03) :191-198

[7]

By A, 1999, CRIT CARE MED, V1, DOI [10.1164/ajrccm.161.supplement_3.ats600, DOI 10.1164/AJRCCM.161.SUPPLEMENT_3.ATS600]

[8] Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice [J].

Cantini, Fabrizio ;

Nannini, Carlotta ;

Niccoli, Laura ;

Iannone, Florenzo ;

Delogu, Giovanni ;

Garlaschi, Giacomo ;

Sanduzzi, Alessandro ;

Matucci, Andrea ;

Prignano, Francesca ;

Conversano, Michele ;

Goletti, Delia .

AUTOIMMUNITY REVIEWS, 2015, 14 (06) :503-509

[9] Tuberculous Uveitis [J].

Cunningham, Emmett T., Jr. ;

Rathinam, Sivakumar R. ;

Albini, Thomas A. ;

Chee, Soon-Phaik ;

Zierhut, Manfred .

OCULAR IMMUNOLOGY AND INFLAMMATION, 2015, 23 (01) :2-6

[10]

Dalvin Lauren A, 2017, J Clin Tuberc Other Mycobact Dis, V7, P13, DOI 10.1016/j.jctube.2017.01.003

← 1 2 3 →